Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study

  • Rodríguez, Victoria
  • Alameda, Luis
  • Quattrone, Diego
  • Tripoli, Giada
  • Gayer-Anderson, Charlotte
  • Spinazzola, Edoardo
  • Trotta, Giulia
  • Jongsma, Hannah E
  • Stilo, Simona
  • La Cascia, Caterina
  • Ferraro, Laura
  • La Barbera, Daniele
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Bonora, Elena
  • Jamain, Stéphane
  • Selten, Jean-Paul
  • Velthorst, Eva
  • de Haan, Lieuwe
  • Llorca, Pierre-Michel
  • Arrojo, Manuel
  • Bobes, Julio
  • Bernardo, Miguel
  • Arango, Celso
  • Kirkbride, James
  • Jones, Peter B
  • Rutten, Bart P
  • Richards, Alexander
  • Sham, Pak C
  • O'Donovan, Michael
  • Van Os, Jim
  • Morgan, Craig
  • Di Forti, Marta
  • Murray, Robin M
  • Vassos, Evangelos
Schizophrenia (SZ), bipolar disorder (BD) and depression (D) run in families. This susceptibility is partly due to hundreds or thousands of common genetic variants, each conferring a fractional risk. The cumulative effects of the associated variants can be summarised as a polygenic risk score (PRS). Using data from the EUropean Network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) first episode case-control study, we aimed to test whether PRSs for three major psychiatric disorders (SZ, BD, D) and for intelligent quotient (IQ) as a neurodevelopmental proxy, can discriminate affective psychosis (AP) from schizophrenia-spectrum disorder (SSD)., This work was supported by funding from the European Community's Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). VR was funded by a PhD scholarship supported by Lord Leverhulme's Charitable Trust and the Velvet Foundation. EV is funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. CA was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), Fundación Familia Alonso and Fundación Alicia Koplowitz. MB was supported by the Ministry od Economy and Competitivity (PI08/0208; PI11/00325; PI14/00612), Instituto de Salud Carlos III – ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM, by the CERCA Programme/Generalitat de Catalunya and Secretaria d'Universitats i Recerca del Departament d'Economia I Coneixement (2017SGR1355). Departament de Salut de la Generalitat de Catalunya, en la convocatoria corresponent a l'any 2017 de concessió de subvencions del PERIS 2016-2020, modalitat Projectes de recerca orientats a l'atenció primària, amb el codi d'expedient SLT006/17/00345; and grateful for the support of the Institut de Neurociències, Universitat de Barcelona., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Biological underpinnings and genetic predisposition to schizophrenia within microrna-137 regulatory pathways across brain development

  • Stella, Carol
  • Hoyos, Lucía de
  • Mora, Alberto
  • Díaz-Caneja, Covadonga M.
  • Andreu-Bernabeu, Álvaro
  • Costas, Javier
  • Gurriarán, Xaquín
  • Fañanas, Lourdes
  • Bobes, Julio
  • González-Pinto, Ana
  • Crespo-Facorro, Benedicto
  • Vázquez-Bourgon, Javier
  • Martorell, Lourdes
  • Vilella, Elisabet
  • Muntané, Gerard
  • Sánchez-Gistau, Vanessa
  • Moltó, Maria Dolores
  • Rivero, Olga
  • CIBERSAM consortium
  • Arango, Celso
  • González-Peñas, Javier
[Data availability] GWAS summary datasets used in this study have been downloaded from the PGC repository (https://www.med.unc.edu/pgc/download-results/). Gene expression data from brain developmental trajectories (http://www.brainspan.org/) and adult brain (https://gtexportal.org/home/) were downloaded from FUMA platform (https://fuma.ctglab.nl/). Individual genotype data for the CIBERSAM consortium samples (Spain, https://www.cibersam.es/en) used here and analytic code are available from the corresponding author upon reasonable request, since deposit of this data to a public repository is not allowed due to ethical and legal requirements at the participating centers., Previous studies have evaluated the role of the microRNA-137 (miRNA137) regulatory pathway in schizophrenia by using in silico or in vitro predicted target genes. These approaches do not capture the dynamic spatiotemporal nature of the miRNA137 regulatory pathway or tend to overestimate direct miRNA binding sites. To provide a more accurate representation of the miRNA137 pathway during human brain development, we evaluated the biological functionality of direct ex vivo miRNA137 targets previously documented in the early prenatal and adult brain. We studied the role of differential expression and genetic predisposing variation to schizophrenia and related disorders within these miRNA137 targets by gene set enrichment analyses (GSEA) and gene-set based polygenic score predictions in an independent schizophrenia case-control cohort. All results were compared to those from in silico or in vitro predicted targets. Only direct miRNA137 targets at prenatal and adult human brain displayed significant enrichments in synaptic and neuronal functions and captured the transcriptomic and genetic predisposing variation to schizophrenia. Furthermore, while adult target genes showed a more consistent enrichment in predisposing variation to schizophrenia and bipolar disorder in case/control polygenic models, prenatal target genes predicted negative symptomatology in schizophrenia patients. Our results suggest that using direct, temporally specific miRNA137 targets significantly improved the detection of biological mechanisms underlying its relationship with psychosis, clarified the association between schizophrenia and related conditions, and suggested association with specific symptomatology domains at different developmental stages of the disorder., Supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), CIBER -Consorcio Centro de Investigación Biomédica en Red- (CB/07/09/0023), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, (SAM16PE07CP1, PI16/02012, PI17/00997, PI19/01024, PI20/00721, PI22/01824, PI23/00625), the European Union -NextGenerationEU (PMP21/00051), Madrid Regional Government (S2022/BMD-7216 AGES 3-CM), European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394)) European Union Horizon Europe Program (Project Youth-GEMs (Grant agreement No 101057182), the National Institute of Mental Health of the National Institutes of Health, Fundación Familia Alonso, and Fundación Alicia Koplowitz. González-Peñas held a Sara Borrell and a Miguel Servet grant during the development of the research from Instituto de Salud Carlos III (CD20/00118; CP24/00080-DOS). CM Díaz-Caneja has previously held a Juan Rodés Grant from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation (JR19/00024)., Peer reviewed